Sepsis Alliance Institute: Recce Pharmaceuticals

Get More Info from Recce Pharmaceuticals

Submit your contact information below to hear more from Recce Pharmaceuticals as well as get your secret word for the exhibitor scavenger hunt challenge!

[{"type":"text","required":true,"label":"Name","className":"form-control","name":"name","subtype":"text"},{"type":"text","subtype":"email","required":true,"label":"Work Email","description":"We will contact you using this email address. If you do not have a work email, enter your personal email address.","className":"form-control","name":"email"},{"type":"text","required":true,"label":"Title","className":"form-control","name":"text-1689944371204","subtype":"text"},{"type":"radio-group","required":true,"label":"What is your role?","name":"radio-group-1677071010442","values":[{"label":"Nurse","value":"Nurse","selected":false},{"label":"Advanced Practice Provider (CNS, NP, PA)","value":"Advanced Practice Provider (CNS, NP, PA)","selected":false},{"label":"Physician","value":"Physician","selected":false},{"label":"Emergency Medical Responder","value":"Emergency Medical Responder","selected":false},{"label":"Pharmacist","value":"Pharmacist","selected":false},{"label":"Medical Technologist","value":"Medical Technologist","selected":false},{"label":"Respiratory Therapist","value":"Respiratory Therapist","selected":false},{"label":"Physical / Occupational Therapist","value":"Physical / Occupational Therapist","selected":false},{"label":"Social Worker / Mental Health Professional","value":"Social Worker / Mental Health Professional","selected":false},{"label":"Student","value":"Student","selected":false},{"label":"IT Professional","value":"IT Professional","selected":false},{"label":"Healthcare Executive / Leader","value":"Healthcare Executive / Leader","selected":false},{"label":"Sepsis Survivor / Patient / Family / Caregiver","value":"Sepsis Survivor / Patient / Family / Caregiver","selected":false},{"label":"Other","value":"Other","selected":false}]},{"type":"text","required":true,"label":"Organization","className":"form-control","name":"company","subtype":"text"},{"type":"text","required":true,"label":"City","className":"form-control","name":"country","subtype":"text"},{"type":"text","required":true,"label":"State","className":"form-control","name":"text-1686164765219","subtype":"text"}]

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

Learn More